Novan Inc
F:6LUA
Novan Inc
Other Current Assets
Novan Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Other Current Assets
$6.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Assets
$4.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Assets
$1.8B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Assets
$2.4B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-10%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Assets
$9.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Assets
$20.5B
|
CAGR 3-Years
96%
|
CAGR 5-Years
45%
|
CAGR 10-Years
39%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Other Current Assets?
Other Current Assets
6.9m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Other Current Assets amounts to 6.9m USD.
What is Novan Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
42%
Over the last year, the Other Current Assets growth was 166%. The average annual Other Current Assets growth rates for Novan Inc have been 62% over the past three years , 42% over the past five years .
